Co-Founder
Back to portfolio

Anvesana is leveraging our RNAseq analysis platform to treat rare genetic disorders caused by gene dosage effects.
- Invested: 2023
- Web: linkedin/anvesana
Partner in charge
About
Anvesana is developing therapeutics to treat diseases caused by insufficient protein production. Our core technology consists of an RNA-sequence analysis pipeline developed in the laboratory of Dr. Thomas Tuschl. Our platform can query mRNA sequence data to identify regions that can be targeted to up-regulate gene expression. Hundreds of rare genetic diseases are caused by insufficient protein production. Many of these have devastating effects on the affected individual and have no approved disease-modifying therapy.